Welcome to Glialogix, Inc.
Glialogix's therapeutic strategy is to inhibit excessive glutamatergic signaling upstream of the classic glutamate signaling receptors, thereby attenuating neuronal hyper-excitability and excitotoxicity without impairing neurological function.
Anti-glutamatergics are clinically validated in neuropathic pain, epilepsy and neurodegenerative diseases such as ALS, Parkinson's and Alzheimer's disease. Prior attempts to inhibit excessive glutamate signaling have focused on targeting the vesicular release of glutamate or individual downstream glutamate receptors, such as the NMDA or AMPA receptors. While such an approach has yielded several compounds which have demonstrated clinical efficacy (i.e. Lyrica for neuropathic pain and epilepsy, Riluzole for ALS, Memantine for AD), this approach does not target non-vesicular release of glutamate from glial cells or dying neurons, nor does it target excessive signaling at any of the other glutamate receptors. Additionally, the approach of targeting a subset of glutamate receptors has often been associated with considerable on-target toxicity. Glialogix has identified a novel, druggable target expressed by activated glial cells that has compelling attributes not found in other targets within the glutamate pathway, and the inhibition of this target should serve to lower the overall level of glutamate in disease states.
Glialogix has further identified GLX1112 as an antagonist to this target. GLX1112 is a small molecule, on-market drug used clinically for non-neurological conditions. It is currently off-patent and has an excellent safety record. GLX1112 has demonstrated significant efficacy in preclinical models of neuropathic pain and epilepsy, and the company has shown that GLX1112 achieves therapeutically relevant concentrations in the CNS.
In collaboration with an experienced formulation partner, Glialogix is pursuing a reformulation strategy for use of GLX1112 in neurological indications. The company's goal is to file an IND on reformulated GLX1112 in less than 18 months.